Trial Profile
A phase II study of nedaplatin plus irinotecan for stage III/IV and EGFR mutation negative non-small cell lung cancer with high-risk factors.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2015
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Nedaplatin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jan 2013 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network - Japan.
- 21 Nov 2012 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.
- 07 Oct 2011 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network - Japan.